310 related articles for article (PubMed ID: 24332379)
1. Predictors of anti-VEGF treatment response in neovascular age-related macular degeneration.
Finger RP; Wickremasinghe SS; Baird PN; Guymer RH
Surv Ophthalmol; 2014; 59(1):1-18. PubMed ID: 24332379
[TBL] [Abstract][Full Text] [Related]
2. Variants in the VEGFA gene and treatment outcome after anti-VEGF treatment for neovascular age-related macular degeneration.
Abedi F; Wickremasinghe S; Richardson AJ; Makalic E; Schmidt DF; Sandhu SS; Baird PN; Guymer RH
Ophthalmology; 2013 Jan; 120(1):115-21. PubMed ID: 23149126
[TBL] [Abstract][Full Text] [Related]
3. Polymorphisms in vascular endothelial growth factor receptor 2 are associated with better response rates to ranibizumab treatment in age-related macular degeneration.
Hermann MM; van Asten F; Muether PS; Smailhodzic D; Lichtner P; Hoyng CB; Kirchhof B; Grefkes C; den Hollander AI; Fauser S
Ophthalmology; 2014 Apr; 121(4):905-10. PubMed ID: 24365177
[TBL] [Abstract][Full Text] [Related]
4. Genetic influences on the outcome of anti-vascular endothelial growth factor treatment in neovascular age-related macular degeneration.
Abedi F; Wickremasinghe S; Richardson AJ; Islam AF; Guymer RH; Baird PN
Ophthalmology; 2013 Aug; 120(8):1641-8. PubMed ID: 23582991
[TBL] [Abstract][Full Text] [Related]
5. Role of vascular endothelial growth factor polymorphisms in the treatment success in patients with wet age-related macular degeneration.
Boltz A; Ruiß M; Jonas JB; Tao Y; Rensch F; Weger M; Garhöfer G; Frantal S; El-Shabrawi Y; Schmetterer L
Ophthalmology; 2012 Aug; 119(8):1615-20. PubMed ID: 22521084
[TBL] [Abstract][Full Text] [Related]
6. Cumulative effect of risk alleles in CFH, ARMS2, and VEGFA on the response to ranibizumab treatment in age-related macular degeneration.
Smailhodzic D; Muether PS; Chen J; Kwestro A; Zhang AY; Omar A; Van de Ven JP; Keunen JE; Kirchhof B; Hoyng CB; Klevering BJ; Koenekoop RK; Fauser S; den Hollander AI
Ophthalmology; 2012 Nov; 119(11):2304-11. PubMed ID: 22840423
[TBL] [Abstract][Full Text] [Related]
7. The impact of anti-vascular endothelial growth factor treatment on quality of life in neovascular age-related macular degeneration.
Finger RP; Guymer RH; Gillies MC; Keeffe JE
Ophthalmology; 2014 Jun; 121(6):1246-51. PubMed ID: 24518613
[TBL] [Abstract][Full Text] [Related]
8. Defining response to anti-VEGF therapies in neovascular AMD.
Amoaku WM; Chakravarthy U; Gale R; Gavin M; Ghanchi F; Gibson J; Harding S; Johnston RL; Kelly SP; Lotery A; Mahmood S; Menon G; Sivaprasad S; Talks J; Tufail A; Yang Y
Eye (Lond); 2015 Jun; 29(6):721-31. PubMed ID: 25882328
[TBL] [Abstract][Full Text] [Related]
9. Clinical utilization of anti-VEGF agents and disease monitoring in neovascular age-related macular degeneration.
Holekamp NM; Liu Y; Yeh WS; Chia Y; Kiss S; Almony A; Kowalski JW
Am J Ophthalmol; 2014 Apr; 157(4):825-833.e1. PubMed ID: 24388973
[TBL] [Abstract][Full Text] [Related]
10. Management of submacular hemorrhage secondary to neovascular age-related macular degeneration with anti-vascular endothelial growth factor monotherapy.
Shienbaum G; Garcia Filho CA; Flynn HW; Nunes RP; Smiddy WE; Rosenfeld PJ
Am J Ophthalmol; 2013 Jun; 155(6):1009-13. PubMed ID: 23465269
[TBL] [Abstract][Full Text] [Related]
11. Ranibizumab versus Bevacizumab for Neovascular Age-related Macular Degeneration: Results from the GEFAL Noninferiority Randomized Trial.
Kodjikian L; Souied EH; Mimoun G; Mauget-Faÿsse M; Behar-Cohen F; Decullier E; Huot L; Aulagner G;
Ophthalmology; 2013 Nov; 120(11):2300-9. PubMed ID: 23916488
[TBL] [Abstract][Full Text] [Related]
12. Comparison of outcomes from a phase 3 study of age-related macular degeneration with a matched, observational cohort.
Gillies MC; Walton RJ; Arnold JJ; McAllister IL; Simpson JM; Hunyor AP; Guymer R; Essex RW; Morlet N; Barthelmes D
Ophthalmology; 2014 Mar; 121(3):676-81. PubMed ID: 24290801
[TBL] [Abstract][Full Text] [Related]
13. Super-dose anti-VEGF (SAVE) trial: 2.0 mg intravitreal ranibizumab for recalcitrant neovascular macular degeneration-primary end point.
Brown DM; Chen E; Mariani A; Major JC;
Ophthalmology; 2013 Feb; 120(2):349-54. PubMed ID: 23131717
[TBL] [Abstract][Full Text] [Related]
14. Outcomes of cataract surgery in patients with neovascular age-related macular degeneration in the era of anti-vascular endothelial growth factor therapy.
Tabandeh H; Chaudhry NA; Boyer DS; Kon-Jara VA; Flynn HW
J Cataract Refract Surg; 2012 Apr; 38(4):677-82. PubMed ID: 22284725
[TBL] [Abstract][Full Text] [Related]
15. Retreatment with anti-vascular endothelial growth factor therapy based on changes in visual acuity after initial stabilization of neovascular age-related macular degeneration: 3-year follow-up results.
Dunavoelgyi R; Sacu S; Eibenberger K; Palkovits S; Leydolt C; Pruente C; Schmidt-Erfurth U
Retina; 2012 Sep; 32(8):1471-9. PubMed ID: 22414958
[TBL] [Abstract][Full Text] [Related]
16. Prognosti implications of pigment epithelial detachment in bevacizumab (avastin)-treated eyes with age-related macular degeneration and choroidal neovascularization.
Freeman WR; Kozak I; Yuson RM; Nigam N; Cheng L; Mojana F
Retina; 2011 Oct; 31(9):1812-8. PubMed ID: 21866073
[TBL] [Abstract][Full Text] [Related]
17. Vascular endothelial growth factor in patients with exudative age-related macular degeneration treated with ranibizumab.
Muether PS; Hermann MM; Viebahn U; Kirchhof B; Fauser S
Ophthalmology; 2012 Oct; 119(10):2082-6. PubMed ID: 22920670
[TBL] [Abstract][Full Text] [Related]
18. VEGFR2 Gene Polymorphisms and Response to Anti-Vascular Endothelial Growth Factor Therapy in Age-Related Macular Degeneration.
Hagstrom SA; Ying GS; Maguire MG; Martin DF; ; Gibson J; Lotery A; Chakravarthy U;
Ophthalmology; 2015 Aug; 122(8):1563-8. PubMed ID: 26028346
[TBL] [Abstract][Full Text] [Related]
19. CFH, VEGF and HTRA1 promoter genotype may influence the response to intravitreal ranibizumab therapy for neovascular age-related macular degeneration.
McKibbin M; Ali M; Bansal S; Baxter PD; West K; Williams G; Cassidy F; Inglehearn CF
Br J Ophthalmol; 2012 Feb; 96(2):208-12. PubMed ID: 21558292
[TBL] [Abstract][Full Text] [Related]
20. Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age-related macular degeneration.
Cunningham ET; Feiner L; Chung C; Tuomi L; Ehrlich JS
Ophthalmology; 2011 Dec; 118(12):2447-52. PubMed ID: 21872935
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
